Investor Relations

Elevating the treatment of cancer 

Join us to build a future in which each patient has access to the right physicians, the right tests, and the right therapeutics to treat their individual tumor.

Corporate Overview
Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. 
Together with our peers, we work towards a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. 
Details on CRESTONE are available at For more information visit
Stock Information
Market Cap
Stock Information
Latest news & updates
Nov 30, 2022

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced...

Nov 3, 2022

On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023 Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the...

Aug 4, 2022

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions...

All Releases

Sign Up For Alerts

Investor updates

Sign up for our investor mailing list below to receive the have the latest news and financials from Elevation Oncology delivered to your inbox.